CD8A and hepatitis B virus infection: Indeed, in patients with multiple sclerosis, ocrelizumab was associated with reactivation of hepatitis B. Of note, CD-20 cell depletion impairs the B-cell dependent CD8 T-cell activation, reducing the cytotoxic defense against the hepatitis B virus.20